Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 6 Gynecologic 4 Genitourinary 3 Thoracic 1 Sarcoma 1 Other solid neoplasm 1 Other hematologic neoplasm 1 Myeloid 1 Lymphoid 1 Head & Neck 1 Dermatologic 1 CNS 1 Breast 1

Conditions

Interventions

pembrolizumab 326 Nivolumab 289 Ipilimumab 260 Cyclophosphamide 193 aldesleukin 145 Interleukin-2 109 fludarabine phosphate 106 Temozolomide 83 Dacarbazine 81 fludarabine 80 Radiotherapy 74 trametinib 73 Vemurafenib 69 dabrafenib 66 Biopsy 65 sargramostim 50 Bevacizumab 50 Radiosurgery 49 Paclitaxel 49 Peripheral Blood Stem Cell Transplantation 48 Carboplatin 48 Magnetic Resonance Spectroscopy 47 Imiquimod 47 Aminolevulinic Acid 47 binimetinib 45 Cisplatin 45 CTLA-4 Antigen 43 cemiplimab 42 atezolizumab 41 Specimen Handling 40

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × irofulven × Dermatologic × Clear all

NCT00005968 2013-05-30

Irofulven in Treating Patients With Stage IV Melanoma

University of Colorado, Denver

Phase 2 Completed

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡